Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35446 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Ranjit Banwait und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology Oncology, UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Furans, Ketones, Neoplasms. Die Arbeit nennt 19 Literaturangaben. Gefördert von: EISAI.
Abstract (Originalsprache)
This pilot phase II study evaluated the combination of lenvatinib, a multi‐kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angiogenesis and resistance mechanisms to anti‐angiogenic therapies were primary motivations for combining these agents. The trial enrolled 29 patients, heavily pretreated with at least three prior lines of chemotherapy, and aimed to assess the efficacy and safety of the combination therapy. Overall response rate (ORR) was 24% with the highest responses observed in breast cancer (29%) and lung cancer (33%) patients. Median progression‐free survival (PFS) was 7.4 months (95% CI 4.5, NA), and overall survival (OS) was 8.2 months (95% CI 6.4 to 14.9). A significant improvement in both OS and PFS was found in vimentin‐negative patients, suggesting that vimentin expression may be a predictor of treatment response. The most common treatment‐related adverse events (TRAEs) were oral mucositis, fatigue, neutropenia, and nausea. Grade ≥3 TRAEs included neutropenia (34.5%), febrile neutropenia (17.2%), and hypertension (13.8%), with one fatal case of sepsis reported. While the study demonstrated the potential of lenvatinib and eribulin in advanced solid tumors, particularly breast and lung cancers, it also highlighted the need for further investigation into biomarkers like vimentin to predict therapeutic outcomes. The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology Oncology, UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA.
- Biostatistics Division, Department of Population Health Sciences, UT Health San Antonio, San Antonio, Texas, USA.
- Department of Medicine, Division of Pathology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA.
ORCID-Profile: Virginia Kaklamani
Förderung
- EISAI
Zitieren
APA
Banwait, R., Ko, H., Michalek, J., Liu, Q., Lathrop, K., Bowhay-Carnes, E., Fotopoulos, G., Sarantopoulos, J., Elledge, R., Taverna, J., Karnad, A., Siziopikou, K. P., & Kaklamani, V. (2025). Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. International Journal of Cancer. https://doi.org/10.1002/ijc.35446
Vancouver
Banwait R, Ko H, Michalek J, Liu Q, Lathrop K, Bowhay-Carnes E, et al. Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. International Journal of Cancer. 2025. doi:10.1002/ijc.35446
BibTeX
@article{Banwait2025,
author = {Banwait, Ranjit and Ko, Heidi and Michalek, Joel and Liu, Qianqian and Lathrop, Kate and Bowhay-Carnes, Elizabeth and Fotopoulos, Georgios and Sarantopoulos, John and Elledge, Richard and Taverna, Josephine and Karnad, Anand and Siziopikou, Kalliopi P and Kaklamani, Virginia},
title = {Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35446}
}
EUVIMED